Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.42 |
| ▸ | SCD | O00767 | 2/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787325 | 0.85 | P2RX7 (0.37) | P2RX7SCDRBP4RORCTRPV1 | |
| SCHEMBL3793484 | 0.84 | P2RX7 (0.35) | P2RX7SCDRBP4RORCABL1 | |
| SCHEMBL3790298 | 0.82 | P2RX7 (0.37) | P2RX7SCDRBP4RORC | |
| SCHEMBL3684563 | 0.80 | P2RX7 (0.34) | P2RX7SCDRORC | |
| SCHEMBL3786771 | 0.80 | P2RX7 (0.33) | P2RX7SCDRORC | |
| SCHEMBL3790304 | 0.79 | P2RX7 (0.33) | P2RX7RORC | |
| SCHEMBL13229244 | 0.79 | ULK1 (0.35) | P2RX7SCDRORCTRPV1USP2 | |
| SCHEMBL3691038 | 0.79 | PTK6 (0.35) | P2RX7RORC | |
| SCHEMBL3789564 | 0.78 | ULK1 (0.33) | P2RX7 | |
| SCHEMBL3786774 | 0.78 | P2RX7 (0.32) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | P2RX7 589/4885SCD 1226/4885RBP4 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.